Fig. 2: MAb-9D5 does not provide postexposure protection. | Nature Communications

Fig. 2: MAb-9D5 does not provide postexposure protection.

From: Nucleocapsid protein-specific monoclonal antibodies protect mice against Crimean-Congo hemorrhagic fever virus

Fig. 2

A IFNAR−/− mice (N = 3) (circles, squares and right side up triangles) were euthanized four days post infection with strain IbAr 10200 or uninfected (N = 1) (upside down triangles), and the presence of NP, GC, and GP38 proteins in the sera was determined by MAGPIX assay. The line shows the mean of the two displayed replicates. B IFNAR−/− mice (N = 10 per group) were treated with two doses of the mAb-9D5 (1 mg/dose) on days −1/ + 3 (black circle) or +1/ + 4 (red square) or isotype control antibody days +1/ + 3 (aqua triangle) and survival and group weight monitored. Mice were SC-infected with CCHFV strain IbAr 10200 on day 0 and survival and weight monitored. Log-rank test comparing each treatment group to the isotype control; ***P = 0.0004. Source data is provided.

Back to article page